Vismodegib (VISMO), a hedgehog pathway inhibitor (HPI), in advanced basal cell carcinoma (aBCC): STEVIE study primary analysis in 1215 patients (pts).
Johan Hansson(Karolinska Institutet), Nicole Basset‐Séguin(Université Paris Cité), Natalie Dimier(Roche (United Kingdom)), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Petr Arenberger(Charles University), A. Raimundo(IPO Porto), Axel Hauschild(University Hospital Schleswig-Holstein), Lisa Licitra(University of Milan), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Kate Fife(Addenbrooke's Hospital), Jean‐Jacques Grob(Aix-Marseille Université), B. Guillot(Université de Montpellier), Nicolás Meyer(Hôpitaux Universitaires de Strasbourg), Laurent Mortier, L. Thomas(University of Liverpool), Rainer Kunstfeld(Vienna General Hospital), Reinhard Dummer(University Hospital of Zurich), Brigitte Dréno(Nantes Université), Ioannis Xynos(AstraZeneca (United Kingdom)), Emi Dika(University of Catania)
Cited by 7
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k